FDA Approves Onapgo for Parkinson's, GLP-1 Medications, and U.S.-Canada Trade Tensions

In this episode, Dr. Chi-Ming Chow begins with an exploration of the role of a fentanyl czar in strengthening Canada-U.S. border security, providing a historical context of political 'czars'. He then discusses the FDA's approval of Onapgo, a new treatment for Parkinson's disease. The episode moves on to address Canada-U.S. trade tensions and their economic impact on consumers. Dr. Chow examines the reasons behind the discontinuation of GLP-1 medications and analyzes former President Trump's influence on U.S. healthcare policy and its global ramifications. The episode concludes with his closing remarks, summarizing the key topics discussed.